Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
about
Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung diseaseAdvancing clinical development pathways for new CFTR modulators in cystic fibrosisTargeted therapies to improve CFTR function in cystic fibrosisThe evolution of blood-spot newborn screeningCystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesCFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisCurrent and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its SymptomsClosed circuit rebreathing to achieve inert gas wash-in for multiple breath wash-outPaediatrics: messages from MunichSustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study.CFTR Modulators for the Treatment of Cystic Fibrosis.Shortened Lung Clearance Index is a repeatable and sensitive test in children and adults with cystic fibrosis.PharmGKB summary: very important pharmacogene information for CFTRReduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis.Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesiaInterpretation of lung function in infants and young children with cystic fibrosis.ATS core curriculum 2014: part IV. Pediatric pulmonary medicine.Novel outcome measures for clinical trials in cystic fibrosisPharmacogenetic Markers of Drug Efficacy and Toxicity.Lung Clearance Index (LCI) is Stable in Most Primary Ciliary Dyskinesia (PCD) Patients Managed in a Specialist Centre: a Pilot Study.Current Progress in Therapeutic Gene Editing for Monogenic DiseasesChest physiotherapy can affect the lung clearance index in cystic fibrosis patients.New drug developments in the management of cystic fibrosis lung disease.The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis.Best practices in the treatment of early cystic fibrosis lung disease.The use of multiple breath washout for assessing cystic fibrosis in infants.Developments in multiple breath washout testing in children with cystic fibrosis.Progression of Lung Disease in Preschool Patients with Cystic Fibrosis.Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop ReportCFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor.Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis.PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.Inter-test reproducibility of the lung clearance index measured by multiple breath washout.Lung clearance index (LCI) as a predictor of exercise limitation among CF patients.Lung clearance index response in patients with CF with class III CFTR mutations.Wavering in the breeze: is multiple breath washout useful in primary ciliary dyskinesia?Leaks during multiple-breath washout: characterisation and influence on outcomes.
P2860
Q26766313-15E759DF-A7A9-4771-A4E0-F3E01A8562F2Q26768266-71C1553B-1229-4CA5-A669-E4553512D38DQ26781441-3EF38EBF-C903-4DCC-A00A-2D2FE62106B3Q27023046-293CB5AF-30AB-4B65-9924-7DDC655738EBQ28073063-858208C5-F5C5-4776-AE7B-93A570BB2535Q28073996-DE158367-8AFA-46B0-8605-18D0E106B5BBQ28077411-76F5DF61-EBCB-4661-B792-FD4A0030B6D5Q28596729-AA435AC2-3157-4440-9356-FF4FD183CA6DQ28596759-FAB6AAEB-5FA7-454E-900E-9D94019F3D46Q30978102-19DBC874-AFC1-4E06-A87A-ADCD391531A0Q31156909-BCDB5FB7-B5A2-4EC4-A2E5-EA724FD2220AQ33920366-CFD33099-56F4-4F8A-8E26-C963F810F9EFQ34419692-276B6D14-BCC9-40A0-BF20-0E0B8B463736Q35108743-E1B7E371-FE46-488C-890A-328E4B95196EQ35628853-7A784DAF-0973-4676-BFFC-17BFF92E2EF4Q35810699-8DF30266-F48A-49D0-A1E4-69DDE63BD573Q36083767-BBCD5CC1-8769-4202-A2A5-00F2AFB774B0Q38221780-F1DFDA32-D52B-408B-AE45-BA3CDB442946Q38303770-82982CE9-E1E8-4950-A178-C23CC36A92E3Q38340406-55285348-6C24-4547-AAF0-2A53E6B940D9Q38419534-760D70E3-0292-4F96-9454-405CE494C52FQ38668720-48E45C4E-220D-4004-A28F-27775CB7609BQ38696285-3AA7DBCD-7DD4-45B5-A398-4C56AD893354Q38765615-E16B9992-46FC-447E-869E-03EDED45A5E1Q38790382-1490F419-0392-4553-A8F7-08BC2A4B4E9CQ38946518-ADFE6241-0204-4383-BCE5-9C3DB24F6281Q38975705-76B43939-9D4C-4939-B347-016E1B64599CQ39028034-7DD83498-9600-464F-BF59-60DB07D4D6FBQ39031790-7146D327-0C68-457F-859D-B1C3B9EA0A48Q39033015-736D5A53-4FE1-484C-B7E2-64F3F702F82FQ39108525-7314032F-AF7D-4351-A2BF-96BC44F3B199Q40834790-43437495-1F24-4679-8713-02B514BD68DCQ41641680-E3A78DBE-3B94-4D46-B329-95BD6E0A8219Q43246776-D08EBE48-ECB4-4868-9D90-0F8ADF00940DQ46281626-1C57B68E-3B5E-4D8A-A8CE-1A98D9B675CFQ47677495-9E481B10-A39E-4C12-8EC2-804C0F038023Q47761419-DC89E01A-45A3-4720-B584-C12A56D463AEQ51542079-55245AE5-9080-4DC1-BD4D-A7F612B498DDQ51658665-FBE39EF4-66BD-47B2-9A67-B321AFECCF46Q53840223-AC202ED5-899D-4BED-9EA1-7D61DA1E2787
P2860
Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Assessment of clinical respons ...... a randomised controlled trial.
@en
Assessment of clinical respons ...... a randomised controlled trial.
@nl
type
label
Assessment of clinical respons ...... a randomised controlled trial.
@en
Assessment of clinical respons ...... a randomised controlled trial.
@nl
prefLabel
Assessment of clinical respons ...... a randomised controlled trial.
@en
Assessment of clinical respons ...... a randomised controlled trial.
@nl
P2093
P50
P1476
Assessment of clinical respons ...... a randomised controlled trial.
@en
P2093
Carlos E Milla
Helen Sheridan
Jane Davies
Nicholas Bell
Po-Shun Lee
Stephanie D Davis
P304
P356
10.1016/S2213-2600(13)70182-6
P577
2013-09-10T00:00:00Z